ResMed Inc. vs Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) — how do they compare? ResMed Inc. trades at $234.01 (market cap $32.99B), while Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) trades at $58.55 (market cap $11.58B). The key difference: ResMed Inc. is far larger — about 2.8× Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value)'s market cap, and Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) pays the higher dividend (3.73%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) for 0 Days on average.
| RMD | TX | |
|---|---|---|
Market Cap | $32.99B | $11.58B |
Volume | 1,023,381 | 456,367 |
Sector | Health | Basic Materials |
52-Week High | $275.96 | $58.99 |
52-Week Low | $182.82 | $35.26 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | $32.35B | $11.90B |
Dividend Yield | 1.13% | 3.73% |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $235.29, up 0.29% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 27.2% net margins and consistent earnings beats in recent quarters. Recent news highlights include upcoming Q1 2027 earnings and management presentations at healthcare conferences, while analyst consensus remains positive with a $243.56 price target.
RMD presents a favorable investment case with strong profitability metrics and positive earnings momentum, though elevated valuation ratios and ongoing legal investigations warrant caution. The stock's technical strength supports near-term upside potential toward resistance levels, while fundamental growth drivers in sleep therapy demand provide long-term support.
Ternium (TX) trades at $58.99, up 1.81% with strong Q2 2026 earnings beating estimates by 43%. The stock shows solid fundamentals with attractive valuation metrics including P/E of 16.39 and P/S of 0.72. Recent analyst upgrades to Strong Buy highlight improving sentiment as Mexico's steel recovery drives operational momentum and the $4B Pesqueria project promises future capacity growth.
The stock offers value with 7% dividend yield projections and 14.5% upside to $65.52 fair value. Key risks include steel price volatility and trade uncertainty, but declining CapEx should boost free cash flow above 15% yield. Analyst consensus at $57.17 with 50% Buy ratings supports cautious optimism for continued recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Ternium S.A. is a Luxembourg-headquartered steel producer operating an integrated production system, from mining through finished flat and long steel products. It runs 18 production plants and two mining operations across Argentina, Brazil, Colombia, Guatemala, Mexico, and US, serving the automotive, construction, appliance, and energy industries.
Read more on TX →